NCT01178814View on ClinicalTrials.gov

Revlimid in Transfusion Dependent Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 1, 2009

Primary Completion Date

September 1, 2022

Study Completion Date

December 7, 2022

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

Revlimid (Lenalidomide)

The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Columbia University

OTHER